DERIVATION OF HIGHLY MEFLOQUINE-RESISTANT LINES FROM *PLASMODIUM FALCIPARUM* IN VITRO

SHEILA A. PEEL, STEPHEN C. MERRITT,
JEAN HANDY, AND RALPH S. BARIC

Department of Epidemiology, and Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina; Department of Microbiology, George Washington University, Washington, DC

Abstract. Serial passage of a multidrug-resistant clone of *Plasmodium falciparum* in concentrations of mefloquine hydrochloride ranging from 30 to 2,400 ng/ml resulted in the derivation of increasingly resistant parasite lines in vitro. Parasite lines isolated in mefloquine concentrations greater than 300 ng/ml demonstrated increased vacuolization, enhanced pigment production, and increased growth rates as compared with the progenitor clone, W2-mef. Although microdilution incorporation assays demonstrated that the 50% inhibitory concentration (IC₅₀) of mefloquine were similar for all lines, the IC₉₀, IC₉₅, and IC₉₉ levels were significantly increased. Growth rate assays performed in 5% hematocrit suspensions demonstrated different levels of mefloquine resistance among these lines. Under these conditions the most resistant line, Mef 2.4, grew efficiently in approximately 10-fold higher concentrations of mefloquine than the progenitor clone W2-mef. Analysis of drug susceptibility profiles to mefloquine hydrochloride, chloroquine diphosphate, quinine sulfate, and halofantrine hydrochloride indicated that selection for high levels of mefloquine resistance had resulted in significant increases in resistance to halofantrine and increased sensitivity to chloroquine. The phenotypic changes demonstrated in the most resistant line, Mef 2.4, reflect a multidrug resistant-like phenotype, and appear to mimic changes recently reported in drug susceptibility profiles of recrudescence isolates following mefloquine treatment failures in Thailand.

Plasmodium falciparum, the cause of the most lethal form of human malaria, is widespread throughout the tropical world and is one of the most challenging issues in modern tropical health. Since vaccines are not available, chemotherapy represents one of the few methods of control for the 1.6 billion humans at risk of infection.¹ Mefloquine (Lariam®; Hoffman LaRoche, Nutley, NJ) has been approved for chemoprophylaxis and chemotherapy for those at risk of infection with chloroquine-resistant or multiple drug-resistant strains of *P. falciparum*.² Reports of treatment failures from Thailand,³⁻⁶ naturally occurring foci of resistance in the Philippines and West Africa,^{7,8} the induction of resistance in cloned parasites in vitro,^{9,10} and possible cross-resistance to quinine and halofantrine, however, cast doubt on the long-term efficacy of mefloquine,^{6,11} or any of the existing antimalarials, against drug-resistant *P. falciparum*.

The genetic mechanisms that mediate resistance to mefloquine are poorly understood. Rodent malaria easily developed resistance to mefloquine, especially when chloroquine resistance was derived first.^{12,13} A four- to six-fold increased resistance to mefloquine was readily de-

veloped in vitro from a clonal population of *P. falciparum* by continuous drug pressure. The clonal line exhibited two-fold increased resistance to halofantrine and increased susceptibility to chloroquine.¹⁰ In addition, mefloquine resistance in *P. falciparum* in vitro and *P. yoelii* in vivo were reversed by the neuroleptic drug penfluridol.^{13,14} These findings have led to the suggestion that mefloquine resistance may be phenotypically similar to the enhanced drug efflux demonstrated by multidrug-resistant (MDR) tumor cell lines. Resistance in these MDR cell lines is mediated by the activity of an ATP-dependent efflux pump termed the P-glycoprotein.^{15,16}

Recent evidence suggests that mefloquine resistance may also be mediated by point mutations and/or gene amplification events in a P-glycoprotein homolog, the *pfmdr1* gene, and in perhaps one or more additional genes.^{14,17,18} The mefloquine resistance phenotype, however, was not linked to the amplified *pfmdr1* gene following genetic analysis,¹⁹ indicating that the molecular basis for mefloquine and chloroquine resistance has not been established and will require additional study. In this paper, we report the isolation and characterization of a series of progressively

more resistant lines of *P. falciparum* in vitro that will be useful in the study of the mechanisms of mefloquine resistance.

MATERIALS AND METHODS

Parasite lines

The parasite clones W2 and W2-mef, derived at the University of North Carolina,^{10, 20} were gifts from Dr. Ayoade Oduola (now of the University of Ibadan, Ibadan, Nigeria). The W2 clone was originally obtained by single erythrocyte micromanipulation from a 50% mixture of the Sierra Leone I/CDC and Indochina III/CDC parasite lines. The mefloquine resistant clone W2-mef was derived by continuous low-dose mefloquine pressure from the multidrug-resistant but mefloquine-sensitive W2 clone.^{10, 20}

Cultivation of parasites

Parasite lines were grown using modifications of standard methods.²¹⁻²³ Stock cultures were maintained in sealed 25-cm² tissue culture flasks (Corning Glass Works, San Francisco, CA) in a total volume of 5 ml of 6% erythrocyte suspension in RPMI 1640 medium (Sigma, St. Louis, MO) supplemented with 10% heat inactivated human plasma, 2 µg/ml of hypoxanthine (Sigma) and 28 mM NaHCO₃ (Sigma). The erythrocytes used were human type A-positive collected in citrate phosphate dextrose (CPD), CPD-A1, or CPD-A1-Adsol (Fort Bragg, Fayetteville, NC and American Red Cross, Durham, NC). Cultures were grown in the absence of antibiotics, gassed with 5% CO₂, 5% O₂, and 90% N₂ (National Welders, Raleigh, NC), and shaken at 50 rpm in an environmental orbital incubator (New Brunswick Scientific, Edison, NJ) at 37°C, or grown as static cultures at 37°C. Morphology and parasitemia were assessed by microscopic examination of thin blood smears stained with Leuko-Stat (Fisher Scientific, Atlanta, GA). Cultures were routinely diluted into fresh erythrocytes to a 0.1–0.2% parasitemia every 3–4 days. Final parasitemia ranged from 4% to 15% depending on the isolate or clone.

Selection for increased mefloquine resistance

Mefloquine hydrochloride was a gift from the Division of Experimental Therapeutics, Walter

Reed Army Institute of Research (WRAIR), (Washington, DC). Stock solutions were prepared by dissolving mefloquine hydrochloride in 70% ethanol to give a concentration of 1 mg/ml. The solution was incubated at 37°C for 30 min and stored at 4°C protected from light. The appropriate concentration of stock solution was diluted into medium daily for parasite cultivation in the presence of drug.

The original W2-mef line had been selected for resistance to 40 ng/ml of mefloquine.¹⁰ To select for increased mefloquine resistance, W2-mef was continuously exposed to 30 ng/ml of mefloquine until the clone demonstrated morphology and growth rates equivalent to the parental line by microscopic examination. By increasing the concentration by 5–10 ng/ml increments, lines were derived that were resistant to 55 ng/ml of mefloquine. Continuous drug pressure protocols were unsuccessful in selecting for resistance greater than 55 ng/ml.

Protocols were then developed for selection of increased resistance using modifications of techniques described for the selection for highly resistant MDR tumor cell lines and rodent malarial.^{24, 25} High-dose relapse protocols were initiated as follows. Parasites were cultivated in the presence of drug until no parasites were detected on a thin smear, then drug pressure was discontinued. Upon demonstration of healthy ring formation and parasite growth equivalent to controls, cultures were again pressured 3–5 times with the same concentration of drug until a culture was derived that tolerated a higher mefloquine dosage than the parental line as assayed by smear morphology. Parasite lines were developed as described above at each progressively higher concentration until lines that tolerated 75, 100, 150, 300, 400, 1,200, and 2,400 ng/ml of mefloquine (designated Mef 75, Mef 100, Mef 150, Mef 300, Mef 400, Mef 1.2, and Mef 2.4, respectively,) were derived over an 18-month period. Selection levels exceeding 2,400 ng/ml of mefloquine were not successful because of the limits of drug solubility. Aliquots of passage lines that were frozen and stored in liquid nitrogen for future studies are shown in Figure 1.

Drug susceptibility testing

Parasite stabilates were thawed and maintained in the absence of drug for up to one year prior to drug susceptibility assays. Parasites were

washed two times in medium without exogenous hypoxanthine, or were cultivated for one week prior to assay in medium without hypoxanthine supplementation. The semiautomated microdilution technique was used as an index of anti-malarial activity.²⁶ Briefly, 96-well, flat-bottomed microtiter plates were prepared with serial dilutions of drug in duplicate over 520-fold or 1,024-fold concentration ranges. Parasitized erythrocytes at a 1.5% hematocrit with an initial parasitemia of 0.25–0.4% were added to each well, the plates were incubated at 37°C in 5% CO₂, 5% O₂, and 90% N₂ for 24 hr, pulse labeled with ³H-hypoxanthine (0.5 µCi/well, specific activity 1 mCi/mM; ICN Biomedicals, Inc., Costa Mesa, CA) for 18 hr, and harvested at 42–44 hr onto glass fiber filters (Whatman LabSales, Hillsboro, OR) using a Mash II cell harvester (MA Bioproducts, Inc., Walkersville, MD). The 50%, 90%, 95%, and 99% inhibitory concentrations (IC₅₀, 90, 95, and 99, respectively,) of mefloquine hydrochloride (WRAIR), chloroquine diphosphate (Sigma), quinine sulfate (Sigma), and halofantrine hydrochloride (WRAIR) were determined by nonlinear regression analysis of concentration-response data.²⁶

Microscopic assays were also used for an independent determination of inhibitory concentrations of mefloquine. Briefly, 96-well, flat-bottomed microtiter plates (Nunc, Inc., Naperville, IL) were prepared with serial dilutions of drug concentrations in triplicate ranging from 1.2 ng/ml to 1,250 ng/ml of mefloquine. Parasite suspensions of a 1.5% hematocrit with an initial 0.2% parasitemia were added, the plates were gassed, and incubated at 37°C. Smears were made at 44 hr, stained, parasites were counted, and the inhibitory concentration values were calculated. Mean IC₅₀ and IC₉₀ determinations were compared with data from assays set up simultaneously by the ³H-hypoxanthine microdilution method.

Morphologic growth curves

Growth rate assays were performed on the W2 and W2-mef clones and the Mef 300 and Mef 2.4 passage lines in medium containing mefloquine at the approximate IC₅₀ (20 ng/ml) and IC₉₅ (100 ng/ml) level of the Mef 2.4 passage line. Briefly, 10 ml of 5% hematocrit suspensions of control and drug-treated cultures were prepared with an initial parasitemia of 1.3–1.5%.

FIGURE 1. Selection protocol for the derivation of highly resistant passage lines of *Plasmodium falciparum* in vitro with mefloquine (Mef) hydrochloride. Parasite lines shown were stabilized and stored for future studies.

Thin blood smears were taken every 12 hr for 72 hr. The percent parasitemia was determined by counting 2,000–10,000 erythrocytes depending on the percent parasitemia of the culture, and growth curves were constructed. Photographs were taken with Tungsten Balanced Tech Pan film (Eastman Kodak, Rochester, NY) on a Nikon (Melville, NY) FXA microscope. The original magnification was either 1,000× (Figure 2A) or 1,400× (Figure 2 B–F).

Exponential growth rates (R)

The growth rate was analyzed as previously described by the following equation:

$$R = \frac{\ln A_2 - \ln A_1}{t_2 - t_1}$$

where A_1 and A_2 = the number of parasites per milliliter of blood at times t_1 and t_2 , respectively.²³

Morphometric studies

To determine the degree of vacuolization of the parasite clones and lines, the total parasite

FIGURE 2. Modified Giemsa-stained thin blood smears demonstrating parasite morphology. A, enlarged vacuole formation and increased hemozoin production in Mef 2.4 line. The clones W2 (B) and W2-mef (C), and the passage lines Mef 300 (D) and Mef 2.4 (E) were cultivated in 100 ng/ml of mefloquine hydrochloride. The Mef 2.4 line was cultivated in 200 ng/ml of mefloquine hydrochloride (F). (Original magnification $\times 1,000$ for A, and $\times 1,400$ for B-F).

and vacuole areas of 25–40 midstage trophozoites were measured using a software morphometry system (Image Measure; Phoenix Technology, Federal Way, WA) with an image processor (FG-100-AT; Imaging Technology, Woburn, MA). The mean total parasite and vacuole areas

and standard deviation were calculated for W2, W2-mef, and Mef 2.4.

Statistical analysis

All inhibitory concentration measurements, parasite area, vacuole area, merozoite numbers

per schizont, and growth rates were statistically analyzed, and presented as mean $\pm$ standard deviation. A one-way analysis of variance with a pos hoc contrast to compare group means was used to evaluate the statistical significance of measurements.²⁷

RESULTS

Selection for highly resistant parasite lines

The W2-mef clone had exhibited stable mefloquine resistance for three years in the absence of drug when selection protocols for higher resistance levels were initiated. The basic approach for selection of the progressively resistant passage lines is depicted in Figure 1. Since W2-mef did not tolerate 40 ng/ml of drug, the final selection dosage that was used in the derivation of this clone,¹⁰ mefloquine pressure was resumed at a concentration of 30 ng/ml. Parasite growth rates decreased and changes in parasite morphology were observed for the first several weeks of drug pressure. Morphologic changes noted in mefloquine treated cultures included 1) enlargement, swelling, and occasional pigmentation of the ring-stage cytoplasm, 2) vacuolization, enlargement, and rarefaction of the chromatin mass, 3) compact, small, diffusely stained trophozoites marked by vacuolization with dispersal of pigment, 4) mature schizonts that were extremely disorganized with reduced numbers of merozoites that appeared to be disintegrated, and 5) vacuolated erythrocytes. After several weeks of passage in this drug concentration, resistant parasite lines appeared that were morphologically similar to parental controls, and exhibited growth rates equivalent to controls. The mefloquine concentration was then increased. Under the continuous drug pressure protocols described in the Materials and Methods, parasites adapted to 55 ng/ml of mefloquine within 20 weeks. Attempts to isolate lines resistant to levels greater than 55 ng/ml were unsuccessful.

To circumvent this problem, we initiated relapse protocols based on approaches used to isolate highly resistant MDR tumor cells.¹⁶ Drug concentrations were increased (see Figure 1 for parasite lines that were stabilized) as follows. Initially, parasites were cultivated in the presence of drug for no more than two to three days when parasitemias decreased below the limits of detectability ($< 0.001\%$). Detection of par-

asites in culture generally occurred two to four days following cessation of drug pressure. By the fifth re-exposure to drug at concentrations of 300 ng/ml of mefloquine, parasites survived for five to seven days prior to decreasing below detectable limits, and required nine-days incubation in drug-free medium before they were again detected. Parasite lines were eventually isolated that tolerated doses of 1,200 and 2,400 ng/ml for 14 days with continued low-level schizogony, after which they were not detectable in culture until after 31-days incubation in the absence of drug.

Morphologic alterations and growth rate analysis

Morphologic alterations on thin blood smears were observed with the derivation of the Mef 300 line and seen in subsequent parasite lines. An enlarged vacuole was seen in the trophozoite stage and at early chromatin division of the schizont stage (Figure 2A). To document the increased vacuolization in Mef 2.4, the total parasite and vacuole areas of midstage trophozoites of W2, W2-mef, and Mef 2.4 were determined. The mean $\pm$ SD parasite areas for W2, W2-mef, and Mef 2.4 were $12.57 \pm 2.92 \mu\text{m}^2$, $12.19 \pm 2.03 \mu\text{m}^2$, and $12.10 \pm 2.10 \mu\text{m}^2$, respectively. No significant differences were noted among the means ($P = 0.726$). The mean $\pm$ SD vacuole areas of W2, W2-mef, and Mef 2.4 were $0.74 \pm 0.57 \mu\text{m}^2$, $1.59 \pm 0.83 \mu\text{m}^2$, and $5.23 \pm 1.73 \mu\text{m}^2$, respectively. The mean total vacuole area encompassed 5.9% of the total parasite area of W2, 13.0% of the area of W2-mef, and 43.2% of the area of Mef 2.4. Significant increases in total vacuole area were noted in W2-mef and Mef 2.4 as compared with W2 ($P < 0.05$), and between W2-mef and Mef 2.4 ($P < 0.001$). Increased pigment formation was also noted, and has persisted as a permanent morphologic alteration (Figure 2A).

The exponential growth rates (R values) were determined for the progenitor clone, W2-mef, and the Mef 2.4 line. Significant differences were noted in the mean $\pm$ SD R values for Mef 2.4 (1.89 ± 0.22) as compared with those for W2-mef (1.34 ± 0.13) ($P = 0.05$). Merozoite numbers per schizont were determined to ascertain whether increased merozoite formation had resulted during the derivation of Mef 2.4. The mean number of merozoites per schizont was not significantly different among W2 (18.9 ± 1.9), W2-mef

FIGURE 3. Comparative dose-response curves of the clone W2-mef and the passage lines of *Plasmodium falciparum* to mefloquine hydrochloride. In vitro susceptibility profiles of W2-mef (●), Mef 300 (▲), Mef 1.2 (◆), and Mef 2.4 (▼) were generated using ^3H -hypoxanthine incorporation as an index of parasite growth. Control counts per minute ranged from 20,000 to 30,000.

(18.1 ± 2.5), and Mef 2.4 (20.1 ± 2.0) ($P = 0.116$).

Determination of inhibitory concentrations

The dose-response curves of the W2-mef, Mef 300, Mef 1.2, and Mef 2.4 lines against mefloquine as determined by ^3H -hypoxanthine incorporation are shown in Figure 3. The dose-response curves of the Mef 1.2 and 2.4 lines reflect a broadening of the curve that does not return to baseline even when assayed against 500 ng/ml of mefloquine. The Mef 2.4 line was a more vigorous parasite line, since the initial parasitemia had to be significantly reduced (two-fold compared with those of W2 or W2-mef) for radiometric assay or parasite overgrowth significantly affected results. Table 1 lists the mean $\pm$ SD determinations of the estimated

IC_{50} , IC_{90} , IC_{95} , and IC_{99} values for mefloquine against W2, W2-mef, Mef 300, Mef 1.2, and Mef 2.4. No significant change in the IC_{50} was noted in Mef 300 ($P = 0.606$), Mef 1.2 ($P = 0.764$), or Mef 2.4 ($P = 0.704$) as compared with W2-mef. The means of the estimated IC_{90} , IC_{95} , and IC_{99} values were not significantly different between W2-mef and Mef 300 ($P = 0.175$). Significant differences in these values, however, were noted in Mef 1.2 and Mef 2.4 as compared with W2-mef and Mef 300 ($P = 0.001$). No significant difference was noted in the IC_{90} ($P = 0.559$) or IC_{95} ($P = 0.444$) values for Mef 1.2 as compared with Mef 2.4. The mean IC_{90} values for Mef 1.2 and Mef 2.4 demonstrated a 1.5-fold increase, and the mean IC_{95} demonstrated a 1.9-fold increase as compared with W2-mef and Mef 300. The mean IC_{99} was increased 2.8-fold for Mef 1.2 and 2.3-fold for Mef 2.4 as compared with

TABLE 1
Comparative in vitro susceptibility profiles of the *Plasmodium falciparum* clones W2 and W2-mef, and the Mef 300, Mef 1.2, and Mef 2.4 lines to mefloquine hydrochloride*

Clone or line	Estimated inhibitory concentration (ng/ml)			
	IC_{50}	IC_{90}	IC_{95}	IC_{99}
W2	4.89 ± 0.72	11.61 ± 0.67	15.74 ± 1.46	33.76 ± 5.52
W2-mef	15.17 ± 4.02	44.04 ± 9.57	60.23 ± 11.93	117.65 ± 19.80
Mef 300	13.88 ± 1.77	38.82 ± 1.90	56.42 ± 2.93	128.92 ± 7.74
Mef 1.2	14.42 ± 3.15	67.01 ± 2.77	113.84 ± 9.48	339.10 ± 45.50
Mef 2.4	16.13 ± 4.38	64.84 ± 1.91	108.02 ± 14.20	283.07 ± 46.39

* Values are means $\pm$ SD of at least three separate determinations (two serial dilutions per determination).

TABLE 2
Comparison of radiometric and microscopic methods for determination of estimated inhibitory concentrations (IC) of the *Plasmodium falciparum* Mef 2.4 line against mefloquine*

IC	Radiometric	Microscopic
IC ₅₀	14.96 ± 3.94	15.60 ± 0.56
IC ₉₀	66.50 ± 6.25	85.40 ± 7.17

* Values are the mean ± SD in ng/ml.

the means for W2-mef and Mef 300. These results demonstrated that resistance to mefloquine in these passage lines had increased significantly.

Microscopic assays were performed for comparison since previous studies reported a lack of correlation between radiometric and microscopic assays against mefloquine.⁹ The IC₅₀ and IC₉₀ values for Mef 2.4 against mefloquine determined in parallel by both methods are presented in Table 2. No significant differences were noted in the mean IC₅₀ or IC₉₀ values obtained by the two methods ($P = 0.115$).

Parasite lines had been derived that clearly tolerated increased concentrations of mefloquine, yet their IC₅₀ values were unchanged as determined by both radiometric and microscopic dilution assays. Their elevated IC₉₅ and IC₉₉ values were consistent with increased resistance. We therefore sought to determine whether mefloquine tolerance resulted from a small resistant subpopulation that persisted in culture and accounted for sufficient ³H-hypoxanthine incorporation to result in the trailing endpoint of the dose-response curve, but not enough incorporation to increase the IC₅₀ of the entire culture.

Assay data for the Mef 1.2 and 2.4 lines were reanalyzed using a modification of the logistic-logarithmic function that permits the evaluation of a biphasic concentration-response relationship of a mixed culture.²⁰ The results are shown in Figure 4. The first IC₅₀ values were similar (13.78 ± 1.08 for Mef 1.2 and 15.58 ± 1.50 for Mef 2.4) to those presented in Figure 3 and Table 1. The curves had a trailing endpoint that did not return to baseline even at a mefloquine concentration of 1,200 ng/ml (higher dilutions were not possible because of solubility limitations). The values calculated by the curve-fitting program using the assumption that the curve would return to baseline were 1,484.18 ± 534.64 for Mef 1.2 and 1,430.96 ± 539.24

for Mef 2.4, respectively. These results suggested that if a highly resistant subpopulation were present, it would exhibit a very high IC₅₀, and would represent a minor percentage of the parasite population. Determination of a second IC₅₀ for a presumed resistant subpopulation, however, could not be determined with confidence.

Growth curve analysis

The results of the radiometric and microscopic assays, showing an IC₅₀ value of approximately 15 ng/ml of mefloquine, were puzzling since the parasite lines had demonstrated very efficient growth in 55 ng/ml of mefloquine during isolation of the passage series. Growth rates of mefloquine-sensitive W2, the progenitor clone, W2-mef, and the passage lines Mef 300 and Mef 2.4 were analyzed in the presence and absence of drug using conditions that reflected the original selection protocol (10-ml suspensions of a 5% hematocrit). Cultures were inoculated with parasitemias of 1.3–1.5% in mefloquine concentrations ranging from 0 ng/ml to 200 ng/ml. These concentrations were chosen to approximate the range of IC₅₀ to IC₉₉ values of Mef 2.4 against mefloquine by radiometric and microscopic dose-response assays (Tables 1 and 2). The results of these experiments are shown in Figure 5.

Under conditions in which control cultures reached maximum parasitemia within 36 hr, growth of the mefloquine-sensitive W2 clone was rapidly inhibited in either 20 ng/ml or 100 ng/ml of mefloquine (Figure 5A). Parasite morphology demonstrated collapsed trophozoites that appeared tight and darkly stained (Figure 2B). Parasitemia decreased to levels less than 0.001% by 72 hr. In contrast, W2-mef, Mef 300, and Mef 2.4 exhibited growth rates equivalent to untreated controls when cultivated in 20 ng/ml of mefloquine (Figure 5B–D). The W2-mef line was rapidly eliminated from culture in the presence of 50 or 100 ng/ml of mefloquine within 3–4 days (Figure 5B). Parasite morphology demonstrated small, vacuolated, diffusely stained trophozoites with marked dissolution of pigment (hemozoin), and schizonts with reduced numbers of disintegrating merozoites (Figure 2C). The Mef 300 line grew efficiently in 50 ng/ml of mefloquine, but exhibited reduced growth rates in the presence of 100 ng/

FIGURE 4. Dose concentration response analysis of the A, Mef 1.2 and B, Mef 2.4 lines of *Plasmodium falciparum* against mefloquine hydrochloride. Dose response was analyzed using a modification of the logistic-logarithmic function that permits evaluation of a biphasic concentration-response relationship.²⁰ Control counts per minute (cpm) ranged from 20,000 to 38,000.

ml of mefloquine (Figure 5C). Morphology similar to that described for W2-mef was detected after cultivation in 100 ng/ml of mefloquine for three days (Figure 2D). Parasitemia eventually decreased below limits of detectability ($< 0.001\%$) after one week. The most surprising result of these studies was the growth of Mef 2.4 at rates equivalent to controls in the presence of 100 ng/ml of mefloquine (Figure 5D). Parasite morphology appeared to be unaffected by this concentration of drug (Figure 2E); how-

ever, the number of merozoites per schizont was significantly reduced (11.3 ± 1.4 as compared with 20.1 ± 2.0 for untreated controls; $P < 0.001$). Cultivation of Mef 2.4 in 200 ng/ml of mefloquine resulted in a reduction in parasite growth (Figure 5D). Although merozoite numbers were greatly reduced (6.8 ± 1.9 as compared with 20.1 ± 2.0 for untreated controls; $P < 0.001$), schizont formation continued at these drug levels (Figure 2F).

FIGURE 5. Growth curves of A, the mefloquine-sensitive clone W2, B, the mefloquine-resistant clone W2-mef, C, the Mef 300 line, and D, the Mef 2.4 line of *Plasmodium falciparum* cultivated in the presence of 0 ng/ml (●), 20 ng/ml (▲), 50 ng/ml (▼), 100 ng/ml (■), or 200 ng/ml (◆) of mefloquine hydrochloride.

TABLE 3

Fifty percent inhibitory concentration (IC_{50}) determinations for chloroquine diphosphate, halofantrine hydrochloride, and quinine sulfate with *Plasmodium falciparum* clones, W2 and W2-mef, and the Mef 2.4 line*

Clone or line	IC_{50} (ng/ml)		
	Chloroquine	Halofantrine	Quinine
W2	98.87 $\pm$ 2.38	0.38 $\pm$ 0.02	66.21 $\pm$ 14.50
W2-mef	63.81 $\pm$ 0.277	1.45 $\pm$ 0.22	55.82 $\pm$ 7.86
Mef 2.4	49.25 $\pm$ 6.18	3.31 $\pm$ 1.46	77.03 $\pm$ 9.93

* Values are means $\pm$ SD of at least three separate determinations (two separate dilutions per determination).

Cross-resistance

Since an approximate 1.4-fold increased susceptibility to chloroquine and an approximate 2.3-fold increased resistance to halofantrine were noted in the W2-mef line compared with its multidrug-resistant parent W2,¹⁰ drug susceptibility to chloroquine, quinine, and halofantrine was assayed in the resistant passage lines. The IC_{50} determinations for W2, W2-mef, and Mef 2.4 against chloroquine diphosphate, quinine sulfate, and halofantrine are shown in Table 3. These data indicated little difference in susceptibility to quinine in the Mef 2.4 line as compared with W2 and W2-mef ($P = 0.199$). In contrast, the estimated IC_{50} determinations indicated a 1.3-fold increased sensitivity to chloroquine ($P < 0.05$), and an approximate 2.3-fold increased resistance to halofantrine ($P < 0.05$) as compared with W2-mef.

DISCUSSION

A series of progressively more resistant lines of *P. falciparum* was isolated by cultivation in mefloquine concentrations ranging from 30 ng/ml to 2,400 ng/ml. Parasite lines were derived that grow efficiently in 100–200 ng/ml, and that tolerated concentrations of 2,400 ng/ml for extended periods. Persistence in 2,400 ng/ml for periods of up to 14 days with low level schizonts suggested that the parasite could tolerate in vitro dosages approaching the mean $\pm$ SD peak plasma concentrations (1.12 $\pm$ 0.3 μ g/ml) measured in humans following a 1,500-mg dose.²⁸ To our knowledge, no other mefloquine-resistant lines have been derived that tolerate drug doses in vitro that approach pharmacologic levels in humans.

The apparent increased resistance of the passage lines to mefloquine under culture conditions was not confirmed by increased IC_{50} determinations generated by radiometric or microscopic

assays. Comparison of the growth curves (Figure 5) with the assay data (Tables 1 and 2) suggests a likely explanation for this anomaly. The ³H-hypoxanthine assay used 1.5% hematocrit suspensions, while growth curve analysis used 5% hematocrit suspensions, which were also used in maintenance cultures and drug selection protocols. Since mefloquine has been found to bind extensively to phospholipids and erythrocyte membranes with high affinity,²⁹ and to hemoglobin with low affinity,³⁰ the percent hematocrit can greatly alter drug bioavailability to the parasite.

The dose-response curve has been shown to be dramatically modulated by an increased percent hematocrit.^{11, 31} The results of growth rate analysis using 5% hematocrit suspensions clearly indicated that lines had been derived that demonstrated increased resistance as compared with the W2-mef clone. The Mef 300 line grew in 50 ng/ml of mefloquine while W2-mef did not, and the Mef 2.4 line grew in concentrations (100–200 ng/ml) that significantly inhibited Mef 300. These results supported those of a previous study, which demonstrated a three-fold discrepancy between IC_{50} determinations measured by microscopic versus radiometric assays in different percent hematocrit suspensions.⁹ Our results also suggest that growth rate analysis using suspensions of higher hematocrit may better predict resistance to mefloquine, and perhaps other extremely lipophilic drugs, under physiologic conditions. Interestingly, researchers in a Thai study were unable to use in vitro susceptibility profiles of pretreatment isolates (generated by ³H-hypoxanthine assays) to predict subsequent mefloquine treatment failures.⁶

The increased vacuole formation observed in parasite lines with dosages exceeding 300 ng/ml was consistent with studies that demonstrated rapid swelling of the parasite food vacuole following exposure to extremely high (50 μ g/ml)

concentrations of mefloquine.³² Although slight vacuolization is seen at times during in vitro cultivation of *P. falciparum*, the Mef 2.4 line has produced significantly larger vacuoles (43% of the total parasite area) than those seen in other clones and lines cultivated in the laboratory. It is interesting to note that increased vacuolization and increased numbers of lysosome-like vacuoles have been noted in MDR tumor cell lines following selection with cytotoxic concentrations of lipophilic antitumor agents.³³ A hypothesis offered to explain these findings in MDR tumor cells is that vesicular compartmentalization and altered targeting of drug away from cellular targets may play a role in drug resistance mechanisms.³⁴

Increased growth rates have been associated with the development of resistant parasites in vitro and in vivo,³⁵ although it is not clear what parasite processes contribute to this phenomenon. The increased growth demonstrated by the Mef 2.4 line could not be attributed to increased merozoite production since merozoite formation was not significantly different from either W2 or W2-mef. An abbreviated life cycle, and/or enhanced invasion of erythrocytes may contribute to enhanced growth. Enhanced pigment production may also be associated with increased growth since rapidly metabolizing parasites may sequester increased amounts of hemozoin. Alternatively, it may be associated with an altered heme polymerase activity. This enzyme is thought to function in the sequestration of the toxic heme moiety, ferriprotoporphyrin IX, by polymerizing it into hemozoin.^{36, 37} Chloroquine, amodiaquine, and quinidine have been shown to block heme polymerization in vitro, suggesting that this enzyme may be a target for quinoline-containing antimalarials.³⁷

A current controversial hypothesis is that resistance to chloroquine and mefloquine in *P. falciparum* may be similar to the MDR phenotype described in MDR tumor cell lines.³⁸ The classic MDR phenotype characterized by changes in sensitivity to a broad spectrum of related and unrelated drugs, however, has not yet been established in *P. falciparum*. A single well-documented exception may be the in vitro induction of mefloquine resistance in the multidrug-resistant clone, W2, which resulted in altered susceptibility patterns to chloroquine and its analogue halofantrine, which are drugs within the same broad chemical class.¹⁰ The deri-

vation of the Mef 2.4 line from W2-mef also resulted in additional increases in sensitivity to chloroquine and resistance to halofantrine, providing additional support for these findings. Although susceptibility levels to both compounds remained well above levels correlated with resistance in vivo,^{5, 11} these findings suggest that an MDR-like phenotype had been derived in these lines. Alternatively, cross-resistance to halofantrine and susceptibility to chloroquine may be mediated by other mechanisms since efflux of mefloquine has not yet been demonstrated in *P. falciparum*.

The MDR phenotype has been especially difficult to document in vivo since individuals may be coinfecting with singly or multiple drug-resistant strains that may be preferentially selected during treatment regimens. Nevertheless, several interesting observations have been noted in the field following treatment failures.^{4-6, 39} A treatment failure with enpiroline in an experimental volunteer yielded a post-treatment isolate with increased resistance to halofantrine and mefloquine, and increased susceptibility to chloroquine and quinine.⁵ Analysis of recrudescence following treatment failures with mefloquine in Thailand have also demonstrated significant increases in the in vitro resistance to mefloquine, halofantrine, and enpiroline, and significant increases in sensitivity to chloroquine.^{6, 39} These findings imply that resistance mechanisms to mefloquine and halofantrine developed by Mef 2.4 in vitro may be similar to mechanisms of resistance that develop in vivo.

Currently, there are few in vitro models available to study the acquisition of antimalarial resistance that may be correlated with the patterns of resistance emerging in field settings. Our results suggest that not only does the Mef 2.4 model mimic drug susceptibility profiles noted in recrudescence parasites in vivo,^{5, 6, 39} but also appears to parallel, at least in part, the MDR phenotype seen in mammalian tumor cell lines. Progressively resistant parasite lines that tolerate pharmacologic doses of mefloquine provide a unique model system to examine potential biological and molecular processes that may relate to mefloquine resistance. Important areas of investigation with these lines include 1) the study of cross-resistance and collateral sensitivity to related and unrelated compounds, 2) the capacity of reversal agents to restore the efficacy

of existing antimalarials against these lines, 3) the ability of these parasites to compartmentalize or efflux drug, and 4) the identification of genes such as *pfmdr1* that may mediate mefloquine resistance in vitro and in vivo.

Acknowledgments: We thank Tamara Bennett for excellent technical assistance. We are grateful to the staff of the Blood Donor Center at Fort Bragg, North Carolina and the American Red Cross for providing blood and plasma.

Financial support: This work was supported by grants from the U.S. Army (DAMD17-87-C-7242), the John Reed Trust, and the North Carolina Biotechnology Center (9213-ARG-0405). This work was also done during the tenure of an established investigator award to Ralph S. Baric from the American Heart Association (AHA-89-0193).

Authors' addresses: Sheila A. Peel and Ralph S. Baric, Department of Epidemiology, CB 7400, McGavran-Greenberg Hall, School of Public Health, University of North Carolina, Chapel Hill, NC 27599-7400. Stephen C. Merritt, Department of Microbiology, George Washington University, Washington, DC 20052. Jean Handy, CB 7600, Clinical Microbiology and Immunology Laboratories, UNC Hospitals, Chapel Hill, NC 27514.

Reprint requests: Ralph S. Baric, Department of Epidemiology, CB 7400, McGavran-Greenberg, School of Public Health, University of North Carolina, Chapel Hill, NC 27599-7400.

REFERENCES

1. Peters W, 1985. The problem of drug resistance in malaria. *Parasitology* 90: 705-715.
2. Centers for Disease Control, 1990. Recommendations for the prevention of malaria among travelers. *MMWR Morb Mortal Wkly Rep* 39: 1-10.
3. Boudreau EF, Webster HK, Pavanand K, Thosingha L, 1982. Type-II mefloquine resistance in Thailand. *Lancet* 11: 1335.
4. Webster LT, Thaithong S, Pavanand K, Yongvanitchit K, Pinswasdi C, Boudreau EF, 1985. Cloning and characterization of mefloquine-resistant *P. falciparum* from Thailand. *Am J Trop Med Hyg* 43: 1022-1027.
5. Cosgriff TM, Pamplin CL, Canfield CJ, Willet GP, 1985. Mefloquine failure in a case of falciparum malaria induced with a multidrug-resistant isolate in a non-immune subject. *Am J Trop Med Hyg* 34: 692-693.
6. Childs GE, Boudreau EF, Wimonwattee T, Pang L, Milhous WK, 1991. In vitro and clinical correlates of mefloquine resistance of *Plasmodium falciparum* in eastern Thailand. *Am J Trop Med Hyg* 44: 553-559.
7. Smrkovski LL, Buck RL, Alcantara AK, Rodriguez CS, Uylangco CV, 1985. Studies of resistance to chloroquine, quinine, amodiaquine and mefloquine among Philippine strains of *Plasmodium falciparum*. *Trans R Soc Trop Med Hyg* 79: 37-41.
8. Oduola AMJ, Milhous WK, Salako LA, Walker O, Desjardins RE, 1987. Reduced in vitro susceptibility to mefloquine in West African isolates of *Plasmodium falciparum*. *Lancet* ii: 572-573.
9. Lambros C, Notsch JD, 1984. *Plasmodium falciparum*: resistance produced in vitro. *Bull World Health Organ* 62: 433-437.
10. Oduola AJ, Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE, 1988. *Plasmodium falciparum*: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. *Exp Parasitol* 67: 354-360.
11. Milhous WK, Gerena L, Kyle DE, Oduola AMJ, 1989. In vitro strategies for circumventing antimalarial drug resistance. *Prog Clin Biol Res* 313: 61-72.
12. Peters W, Portus JH, Robinson BL, 1977. The chemotherapy of rodent malaria. XXVIII. The development of drug-resistance to mefloquine (WR 142,490). *Ann Trop Med Parasitol* 71: 419-427.
13. Peters W, Robinson BL, 1991. The chemotherapy of rodent malaria. XLVI. Reversal of mefloquine resistance in rodent *Plasmodium*. *Ann Trop Med Parasitol* 85: 5-10.
14. Wilson CM, Serrano AE, Wasley A, Bogenschutz MP, Shankar AH, Wirth DF, 1989. Amplification of a gene related to mammalian *mdr* gene in drug resistant *Plasmodium falciparum*. *Science* 244: 1184-1186.
15. Juliano RL, Ling V, 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta* 455: 152-162.
16. Croop JM, Gros P, Housman DE, 1988. Genetics of multidrug resistance. *J Clin Invest* 81: 1303-1309.
17. Foote SJ, Thompson JK, Cowman AF, Kemp DJ, 1989. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of *P. falciparum*. *Cell* 57: 921-930.
18. Foote SJ, Kyle DE, Martin RK, Oduola AMJ, Forsyth K, Kemp DJ, Cowman AF, 1990. Several alleles of the multidrug resistance gene are closely linked to chloroquine resistance in *Plasmodium falciparum*. *Nature* 345: 255-258.
19. Wellems TE, Panton LJ, Glutzman IY, do Rosario VE, Gwadz RW, Walker-Jonah A, Krogstad DJ, 1990. Chloroquine resistance not linked to *mdr*-like genes in a *Plasmodium falciparum* cross. *Nature* 345: 253-255.
20. Oduola AMJ, Weatherly NF, Bowdre JH, Desjardins RE, 1988. *Plasmodium falciparum*: cloning by single-erythrocyte micromanipulation and heterogeneity in vitro. *Exp Parasitol* 66: 86-95.
21. Trager W, Jensen JB, 1976. Human malarial par-

- asites in continuous culture. *Science* 193: 673-675.
22. Haynes JD, Diggs CL, Hines FA, Desjardins RE, 1976. Culture of human malarial parasites *Plasmodium falciparum*. *Nature* 263: 767-769.
 23. Oduola AMJ, Alexander BM, Weatherly NF, Bowdre JH, Desjardins RE, 1985. Use of non-human plasma for in vitro cultivation and antimalarial drug susceptibility testing of *Plasmodium falciparum*. *Am J Trop Med Hyg* 34: 209-215.
 24. Ozols RF, Cowan K, 1986. New aspects of clinical drug resistance: the role of gene amplification and the reversal of resistance in drug refractory cancer. *Important Adv Oncol*: 129-157.
 25. Peters W, 1968. The chemotherapy of rodent malaria. V. Dynamics of drug resistance, part 1: methods for studying the acquisition and loss of resistance to chloroquine by *Plasmodium berghiei*. *Ann Trop Med Parasitol* 62: 277-287.
 26. Desjardins RE, Canfield CJ, Haynes, Chulay JD, 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. *Antimicrob Agents Chemother* 16: 710-718.
 27. Remington RD, Schork MA, 1985. The analysis of variance. Remington RD, Schork, MA, eds. *Statistics with Applications to the Biological and Health Sciences*. Englewood Cliffs, NJ: Prentice-Hall, Inc., 165-185, 262-292.
 28. Desjardins RE, Pamplin CL, von Bredow J, Barry KG, Canfield CJ, 1979. Kinetics of new antimalarial, mefloquine. *Clin Pharmacol Ther* 26: 372-379.
 29. Chevli R, Fitch CD, 1982. The antimalarial drug mefloquine binds to membrane phospholipids. *Antimicrob Agents Chemother* 21: 581-586.
 30. San George RC, Nagel RL, Fabry ME, 1984. On the mechanism for the red-cell accumulation of mefloquine, an antimalarial drug. *Biochem Biophys Acta* 803: 174-181.
 31. Geary TG, Divo AD, Jensen JB, Zangwill M, Ginsburg H, 1990. Kinetic modelling of the response of *Plasmodium falciparum* to chloroquine and its experimental testing in vitro. *Biochem Pharmacol* 40: 685-691.
 32. Jacobs GH, Aikawa M, Milhous WK, Rabbege JR, 1987. An ultrastructural study of the effects of mefloquine on malarial parasites. *Am J Trop Med Hyg* 36: 9-14.
 33. Zamora JM, Beck WT, 1992. Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells. *Mol Pharmacol* 33: 454-462.
 34. Beck WT, 1987. The cell biology of multiple drug resistance. *Biochem Pharmacol* 36: 2879-2887.
 35. Thaithong S, 1983. Clones of different sensitivities in drug-resistant isolates of *Plasmodium falciparum*. *Bull World Health Organ* 61: 709-712.
 36. Wellems TE, 1992. How chloroquine works. *Nature* 355: 108-109.
 37. Slater AFG, Cerami A, 1992. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. *Nature* 355: 167-169.
 38. Karcz S, Cowman SK, 1991. Similarities and differences between the multidrug resistance phenotype of mammalian tumor cells and chloroquine resistance in *Plasmodium falciparum*. *Exp Parasitol* 73: 233-240.
 39. Webster HK, Boudreau EF, Pavanand K, Yongvanitchit K, Pang LW, 1985. Antimalarial drug susceptibility testing of *Plasmodium falciparum* in Thailand using a microdilution radioisotope method. *Am J Trop Med Hyg* 34: 228-235.